N-n Or N=c(-n)-n Containing (e.g., Hydrazines, Hydrazones, Or Guanidines, Etc.) Patents (Class 514/565)
  • Patent number: 10334846
    Abstract: Compositions and methods for the disinfection of surfaces are provided. The compositions include at least about 40 weight percent of a C1-6 alcohol, and a primary enhancer selected from protein denaturants. The disinfectant composition is characterized by a pH of less than about 3. Broad spectrum efficacy is achieved, and synergistic activity is exhibited against C. difficile spores.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: July 2, 2019
    Assignee: GOJO Industries, Inc.
    Inventors: James Edmund Bingham, David R. Macinga
  • Patent number: 10245245
    Abstract: Compositions for neuroprotection and treatment of neurodegeneration and methods of administering same. In particular, the present invention relates to compositions and methods for preventing or reducing neurodegeneration, such as neurodegeneration caused by Huntington's disease, including administering a daily dose of a composition including an effective amount of creatine hydrochloride to a patient in need thereof. The methods of the present invention allow for lower dosages of supplementation as compared to creatine monohydrate while retaining all of the desired biological effects of creatine supplementation.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: April 2, 2019
    Assignee: Vireo Systems, Inc.
    Inventors: Mark C. Faulkner, Donald W. Miller, Grant M. Hatch
  • Patent number: 10231933
    Abstract: An oral creatine formulation includes soluble creatine and polyethylene glycol, coated with an enteric coating. The most preferred soluble creatine is creatine HCl. The most preferred polyethylene glycols have an average molecular weight of from 3150 to 3685, although for particular formulation formulations and particular uses, the average molecular weight polyethylene glycols may range from 190 to 9000.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: March 19, 2019
    Assignee: CRYXA LLC
    Inventors: F. Joseph Daugherty, John R. Palmer, Michael S. Tempesta
  • Patent number: 10226429
    Abstract: An oral creatine formulation includes soluble creatine and polyethylene glycol, coated with an enteric coating. The most preferred soluble creatine is creatine HCl. The most preferred polyethylene glycols have an average molecular weight of from 3150 to 3685, although for particular formulation formulations and particular uses, the average molecular weight polyethylene glycols may range from 190 to 9000.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: March 12, 2019
    Assignee: CRYXA LLC
    Inventors: F. Joseph Daugherty, John R. Palmer, Jr., Michael S. Tempesta
  • Patent number: 9993447
    Abstract: Formulations of hydrosoluble stable organic salts including, but not limited to, agmatine orotate, agmatine di-hydrochloride, agmatine phosphate, buffered agmatine or spray dried buffered agmatine base, whether alone or in combination with one another, are provided, as well as methods for making same. These agmatine salts may have improved solubility in aqueous and organic media and may have increased absorbability and/or tissue bioavailability in humans and animals when compared to agmatine sulfate. These formulations may be administered as a means for improving athletic performance, training resistance and/or cognitive function. These formulations also may increase cellular uptake of agmatine in an animal or human.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: June 12, 2018
    Assignee: JW Nutritional, LLC
    Inventors: Dragos Alevizache, Jesse Windrix
  • Patent number: 9968581
    Abstract: An anti-inflammatory composition for treatment of inflamed joints. This composition includes an alkali buffered creatine and a cetylated fatty acid. The composition can be used for treating inflammation either by oral ingestion or by topical treatment.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: May 15, 2018
    Inventor: Jeffrey M. Golini
  • Patent number: 9943494
    Abstract: Methods and compositions for treating a complication associated with aneurysmal subarachnoid hemorrhage (SAH), the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof. Methods and compositions for treating vasospasm, the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: April 17, 2018
    Assignee: Vanderbilt University
    Inventors: Marshall L. Summar, Frederick E. Barr, Reid Carleton Thompson
  • Patent number: 9820482
    Abstract: Compositions and methods for the disinfection of surfaces are provided. The compositions include at least about 40 weight percent of a C1-6 alcohol, and a primary enhancer selected from protein denaturants. The disinfectant composition is characterized by a pH of less than about 3. Broad spectrum efficacy is achieved, and synergistic activity is exhibited against C. difficile spores.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: November 21, 2017
    Assignee: GOJO Industries, Inc.
    Inventors: James Edmund Bingham, David R. Macinga
  • Patent number: 9675637
    Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: June 13, 2017
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, acting through Louisiana State University Health Sciences Center, The UAB Research Foundation, Loma Linda University, Wake Forest University
    Inventors: Mark T. Gladwin, Alan N. Schechter, David J. Lefer, Rakesh P. Patel, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Ryszard Pluta, Edward H. Oldfield, Richard O. Cannon, III
  • Patent number: 9662368
    Abstract: The present invention relates to a formulation comprising whey protein or a hydrolysate of whey protein, which formulation is capable of inhibiting the expression of TNF? in lipopolysaccharide-stimulated macrophages in vitro. Also provided are uses of the formulation for attenuating a reduction in muscle function which results from muscle damage and/or for enhancing recovery from muscle damage and/or for enhancing the force generating capacity of muscle and methods of making the formulation.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: May 30, 2017
    Assignee: MURRAY GOULBURN CO-OPERATIVE., LIMITED
    Inventors: Michelle Rowney, Andrew Brown, Yu Pan, Jonathan David Buckley
  • Patent number: 9434729
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of periodontitis and rheumatoid arthritis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: September 6, 2016
    Assignee: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Patent number: 9351926
    Abstract: A novel pharmaceutical formulation includes a four mg per ml (4 mg/mL) Ibuprofen in an aqueous solution of Arginine and Ibuprofen, wherein the molar ratio of Arginine to ibuprofen is more than or equal to 1.000625:1, Tris buffered, isotonic, and adjusted to pH between 7.2-8.5 by addition of 1.0 N HCL, none of the excipients used contains material of animal or human origin. There were no novel excipients used. A method of treating through anti-inflammatory, analgesic, and antipyretic activity: fever, pain, dysmenorrhea and inflammatory diseases are also described. It is also used for pericarditis and patent ductus arteriosus (Patent ductus arteriosus (PDA)), relieve moderate to severe pain, dental pain and pain after an operation, mild to moderate pain including migraine headache, and for short term treatment of pyrexia in children over one year of age. The formulation is meant to be used as ready to use intravenous infusion.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: May 31, 2016
    Assignee: PHARMACEUTICAL SOLUTIONS INDUSTRY LTD.
    Inventors: Khalil A. H. Selmi, Irfan J. M. Jamil, Yahya H. A. Idris
  • Patent number: 9205058
    Abstract: Provided are a tape-type fluorine preparation using a biodegradable polymer and a method of preparing the same, and preferably, a tape-type fluorine preparation which is attached to teeth to gradually release fluorine, thereby maintaining a suitable fluorine concentration in an oral cavity, and self-degraded after a certain amount of time, and a method of preparing the same. The tape-type fluorine preparation includes a pressure-sensitive adhesive sheet containing fluorine and capable of being attached to teeth, and the pressure-sensitive adhesive sheet is formed of a biodegradable hydrophilic polymer in an oral cavity to reduce a rate at which the fluorine is released.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: December 8, 2015
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITY
    Inventors: Sang Ho Lee, In Hwa Lee
  • Patent number: 9072710
    Abstract: The present invention provides a pharmaceutical composition comprising an aqueous solution of an ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition. The invention further provides a method of treating a condition chosen from pain, inflammation, fever, and/or patent ductus arteriosis, comprising administering to a patient in need thereof an effective amount of an aqueous solution a ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition, as well as a method for manufacturing the composition.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: July 7, 2015
    Assignee: Cumberland Pharmaceuticals Inc.
    Inventors: Leo Pavliv, Andrew Vila
  • Patent number: 9072661
    Abstract: The present invention provides a pharmaceutical composition comprising an aqueous solution of an ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition. The invention further provides a method of treating a condition chosen from pain, inflammation, fever, and/or patent ductus arteriosis, comprising administering to a patient in need thereof an effective amount of an aqueous solution a ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition, as well as a method for manufacturing the composition.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: July 7, 2015
    Assignee: Cumberland Pharmaceuticals Inc.
    Inventors: Leo Pavliv, Andrew Vila
  • Publication number: 20150147385
    Abstract: Compositions and methods for the treatment of proliferative disorders including proliferative such as breast, uterine cervical, ophthalmic, and pancreatic cancer by the administration of intravenous synthetic curcumin (S-curcumin) are disclosed herein.
    Type: Application
    Filed: November 21, 2014
    Publication date: May 28, 2015
    Inventor: Lawrence Helson
  • Patent number: 9040577
    Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: May 26, 2015
    Assignee: NeuroDerm, Ltd.
    Inventors: Oron Yacoby-Zeevi, Mara Nemas
  • Patent number: 9040578
    Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: May 26, 2015
    Assignee: NeuroDerm, Ltd.
    Inventors: Oron Yacoby-Zeevi, Mara Nemas
  • Publication number: 20150126605
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Application
    Filed: January 7, 2015
    Publication date: May 7, 2015
    Inventors: Gregory T. Went, Timothy J. Fultz
  • Publication number: 20150126604
    Abstract: The present disclosure includes a formulation of branched chain amino acids and arginine for treatment of diseases for which the pathological mechanism includes autophagy. The formulation includes defined ratios of the branched chain amino acids Isoleucine, Leucine, and Valine along with Arginine. These disease indications include congestive heart failure, myocardial infarction, and ischemia reperfusion injury. Diseases of other organs that involve autophagy are also disclosed. Additionally, methods of using the disclosed formulation to treat these disease indications are provided. The disclosure also describes a kit that includes a lyophilized form of the formulation, a solvent for reconstitution, and instructions directing reconstitution.
    Type: Application
    Filed: March 14, 2014
    Publication date: May 7, 2015
    Inventors: Evan Dale Abel, Christian Michael Riehle
  • Publication number: 20150119465
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Application
    Filed: January 7, 2015
    Publication date: April 30, 2015
    Inventors: Gregory T. Went, Timothy J. Fultz, Timothy S. Burkoth
  • Publication number: 20150110899
    Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia, in particular peripheral artery disease (PAD).
    Type: Application
    Filed: December 22, 2014
    Publication date: April 23, 2015
    Inventors: Christopher KEVIL, Anthony GIORDANO
  • Patent number: 9012508
    Abstract: An effective dose of intravenous ibuprofen administered every 6 hours in surgery patients is a safe and effective way to reduce both pain and the need for morphine. In preferred embodiments, the administration of intravenous ibuprofen starts with the onset of anesthesia.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: April 21, 2015
    Assignee: Cumberland Pharmaceuticals
    Inventor: Leo Pavliv
  • Patent number: 8993581
    Abstract: Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of about sixteen days for a total cycle of about 21 days.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: March 31, 2015
    Assignee: Trustees of Boston University
    Inventors: Susan Perrine, Douglas Faller
  • Patent number: 8987333
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: March 24, 2015
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Publication number: 20150072966
    Abstract: A method of establishing a therapeutic window of wound fluid nitric oxide (WFNO) in the wound of a mammal, the method including: obtaining a wound fluid sample from a mammal; analyzing the WFNO level; determining whether the WFNO is at or below a lower threshold level, or is at or above an upper threshold level; wherein the lower threshold level and upper threshold level define the therapeutic window of WFNO; and treating the mammal with a substance that alters the WFNO level such that the therapeutic window of WFNO in the wound is established.
    Type: Application
    Filed: February 28, 2013
    Publication date: March 12, 2015
    Applicant: 3M INNOVATIVE PROPERTIES COMPANY
    Inventors: Joseph V. Boykin, JR., Stephanie F. Bernatchez, Vinod P. Menon, Joseph J. Stoffel, Joseph A. Tucker
  • Publication number: 20150053211
    Abstract: An aqueous oral spray designed to treat mouth guards against bacterial infection comprising: 1. A naturally derived di-basic amino acid derivative, 2. A natural sweetener which inhibits the adhesion of bacteria to the oral cavity and, 3. Optionally a natural flavor and/or natural dye 4. Optionally a mouth guard surface modified to absorb specific components of above oral aqueous solution so as to render mouth guard more effective overtime in inhibiting microorganism growth on surface and in contact with mouth surfaces compared with unmodified mouth guard surface.
    Type: Application
    Filed: August 26, 2013
    Publication date: February 26, 2015
    Inventors: Richard F. Stockel, Dennis R. Hanlon, Bruce Alan Nascimbeni, John Edward McCaskie
  • Patent number: 8962685
    Abstract: The present invention is directed to a third generation form of creatine, specifically a creatine hydrochloride salt, that drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: February 24, 2015
    Assignees: Vireo Systems, Inc., Board of Regents of the University of Nebraska
    Inventors: Donald W. Miller, Jonathan L. Vennerstrom, Mark C. Faulkner
  • Publication number: 20150038523
    Abstract: The invention relates to compounds of formula (I): wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula (I) for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to alpha-V-beta-integrin antagonists to target cells expressing alpha-V-beta-3.
    Type: Application
    Filed: January 22, 2013
    Publication date: February 5, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Robert Alan Goodnow, Jr., Matthew Michael Hamilton, Agnieszka Kowalczyk, Achyutharao Sidduri
  • Publication number: 20150037405
    Abstract: The present invention relates to pharmaceutical compositions of levodopa and carbidopa. In particular, the invention relates to modified release pharmaceutical compositions of levodopa and carbidopa with at least one organic acidic excipient. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of Parkinson's disease.
    Type: Application
    Filed: August 4, 2014
    Publication date: February 5, 2015
    Inventors: Sushrut Krishnaji Kulkarni, Pavak Rajnikant Mehta, Sameer Sagar Kochar, Krishnakumar Vinubhai Patel
  • Publication number: 20150030579
    Abstract: Hydroxytyrosol or olive juice containing hydroxytyrosol in combination with at least one of the compounds selected from the group consisting of: creatine, coenzyme Q10, resveratrol, caffeine, carnitine, B vitamins (B1, B2, B3, B5, B6, and/or B12) and ginseng (preferably: root) extract. can be used to maintain or increase mitochondrial biogenesis in cardiac muscle, skeletal muscles, and liver tissue.
    Type: Application
    Filed: August 1, 2014
    Publication date: January 29, 2015
    Applicant: DSM IP ASSETS B.V.
    Inventors: Ann FOWLER, Angelika FRIEDEL, Darko KNUTTI, Karin KURATLI, Daniel RAEDERSTORFF, Ying WANG-SCHMIDT, Karin WERTZ
  • Publication number: 20150025063
    Abstract: A method of treating a subject for Parkinson's disease comprises administering said subject a phenylisopropylamine in an amount effective to treat said Parkinson's disease. In some embodiments the method is used to treat at least a motor symptom of Parkinson's disease; in some embodiments the method is used to treat at least a non-motor symptom of Parkinson's disease.
    Type: Application
    Filed: September 30, 2014
    Publication date: January 22, 2015
    Inventors: Marc G. Caron, Tatyana D. Sotnikova, Raul R. Gainetdinov
  • Publication number: 20150010624
    Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.
    Type: Application
    Filed: July 2, 2014
    Publication date: January 8, 2015
    Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
  • Patent number: 8927030
    Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: January 6, 2015
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Mark T. Gladwin, Alan N. Schechter, David J. Lefer, Rakesh P. Patel, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Ryszard Marek Pluta, Edward H. Oldfield, Richard O. Cannon, III
  • Publication number: 20140378534
    Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods.
    Type: Application
    Filed: September 8, 2014
    Publication date: December 25, 2014
    Applicant: THE ROCKEFELLER UNIVERSITY
    Inventors: Sohail F. Tavazoie, Jia M. Loo
  • Patent number: 8895616
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: November 25, 2014
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Patent number: 8895618
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: November 25, 2014
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Patent number: 8895617
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: November 25, 2014
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Patent number: 8895065
    Abstract: There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts thereof from about 10 mg to about 100 mg in extended release and c) entacapone or salts thereof from about 100 mg to about 1000 mg in immediate release form, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: November 25, 2014
    Assignee: Wockhardt Ltd.
    Inventors: Yatendra Kumar Gupta, Girish Kumar Jain, Munish Talwar, Manoj Mashalkar
  • Patent number: 8895615
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: November 25, 2014
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Patent number: 8895614
    Abstract: A method of administering amantadine is provided. The method comprises orally administering to a subject a pharmaceutical composition comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of the amantadine. A dose of the composition provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is less than 40% of the change in amantadine plasma concentration provided by a dose of the same quantity of an immediate release form of amantadine. The change in plasma concentration over time (dC/dT) is measured in a single dose human pharmacokinetic study in a defined time period of 0 to 4 hours after administration. The amantadine, or pharmaceutically acceptable salt thereof, is administered once daily at a dose of 300 to 500 mg per day.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: November 25, 2014
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Publication number: 20140343000
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 and C-3 modified triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: These compounds are useful for the treatment of HIV and AIDS.
    Type: Application
    Filed: July 24, 2014
    Publication date: November 20, 2014
    Inventors: Alicia Regueiro-Ren, Zheng Liu, Jacob Swidorski, Ny Sin, Brian Lee Venables, Sing-Yuen Sit, Yan Chen, Jie Chen, Nicholas A. Meanwell
  • Publication number: 20140343153
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Publication number: 20140343152
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Publication number: 20140343154
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Patent number: 8889740
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: November 18, 2014
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Patent number: 8883131
    Abstract: A synergistic composition, or the use of that composition in the manufacture of a medicament, or a method of treatment including the use of that composition, for the treatment of hair loss and baldness, for combined, sequential or simultaneous administration, in any form, via any biological route. In its optimal embodiment the composition consists, in the form of a lotion: 1600-2400 IU/mL Vitamin A Palmitate, 0.64%-0.96% Thiamine Hydrochloride, 0.64%-0.96% Pyridoxine Hydrochloride, 4.8%-7.2% Niacinamide, 2.85%-5.2% D-Panthenol, 1.6%-2.4% L-Arginine, 3.6%-4.4% Methyl Sulphonyl Methane (MSM), 0.08%-0.12% Ginger Oil, 0.08%-0.12% Cinnamon Oil, 0.0996%-0.1494% Oleoresin Capsicum, 1.3%-1.95% Magnesium, 2.4%-3.6% Zinc, 0.192%-0.288% Manganese, 2.6%-3.9% Urea, 2.4%-3.6% Sodium Glycerophosphate, 4.8%-7.2% L-Lysine HCl, plus Preservatives, Co-solvent (Propylene Glycol), Fragrances, Anti-Oxidant, Cooling agent (Menthol), Emulsifier, and Vehicle (Purified water).
    Type: Grant
    Filed: October 26, 2010
    Date of Patent: November 11, 2014
    Inventors: Robert Peter Taylor, Kartar Singh Lalvani, Ajit Lalvani
  • Publication number: 20140328910
    Abstract: An ingestion method of creatine composition, taking orally the creatine composition with beverage, characterized in that, the creatine composition is taken orally by preparing creatine composition aqueous solution with dissolving the creatine composition over one minute into water heating at 80-100° C. and by mixing the creatine composition aqueous solution with the beverage having ordinary or cool temperature.
    Type: Application
    Filed: November 9, 2012
    Publication date: November 6, 2014
    Inventors: Hirohisa Nishizawa, Haruhiko Sueoka
  • Patent number: 8871810
    Abstract: Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: October 28, 2014
    Assignee: Cumberland Pharmaceuticals Inc.
    Inventors: Leo Pavliv, Amy Dix Rock
  • Publication number: 20140314842
    Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.
    Type: Application
    Filed: July 2, 2014
    Publication date: October 23, 2014
    Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni